Global Minds - A Landmark Trial Deck Study in Dementia Research 

Trial Deck is proud to announce the launch of Global Minds, a major transatlantic research study powered by our platform. Designed to explore the causes and progression of dementia, Global Minds is one of the largest studies of its kind, targeting 50,000 participants across the UK and the United States.

This ambitious initiative is a direct follow-on from the successful UK Minds study and is once again led by the team at Akrivia Health (formerly Cristal Health). Akrivia is a pioneering health data and analytics company focused on transforming mental health research by enabling access to high-quality real-world data. We are delighted to renew our collaboration with Akrivia and support this major partnership with industry and academic stakeholders.

Global Initiative and Akrivia Health have a longstanding relationship, having previously collaborated on the development of the CRIS Platform, the Clinical Record Interactive Search system, which is the world’s largest and most comprehensive repository of anonymised mental health records. Pulling data from over many NHS Trusts, CRIS provides researchers with a secure, searchable interface that supports patient recruitment, site identification, and feasibility assessment for clinical trials.

For the Global Minds study, Trial Deck has developed robust, purpose-built APIs to support large-scale, integrated data capture and automation. One of the core integrations links directly to the CRIS platform, allowing participant eligibility to be verified via NHS number. This significantly accelerates the trial startup process and ensures compliance and accuracy in participant matching.

In addition, Trial Deck has integrated with KAIZEN BioResource, the specialist sample logistics provider, via a dedicated API. This feature enables participants to track the real-time status of their biological samples, improving transparency and providing peace of mind through a seamless digital experience.

Global Minds represents a leap forward in how large-scale studies can be conducted using technology. By combining data-rich environments, bespoke digital infrastructure, and strong research partnerships, the study sets a new standard for clinical research in dementia.

We’re delighted to be working alongside Akrivia Health once again.

Visit the trial website: www.globalminds.org